MX2020005659A - Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia. - Google Patents

Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.

Info

Publication number
MX2020005659A
MX2020005659A MX2020005659A MX2020005659A MX2020005659A MX 2020005659 A MX2020005659 A MX 2020005659A MX 2020005659 A MX2020005659 A MX 2020005659A MX 2020005659 A MX2020005659 A MX 2020005659A MX 2020005659 A MX2020005659 A MX 2020005659A
Authority
MX
Mexico
Prior art keywords
parp inhibitor
resistant ovarian
breast cancer
ovarian cancer
cancer
Prior art date
Application number
MX2020005659A
Other languages
English (en)
Inventor
Quanren Wang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020005659A publication Critical patent/MX2020005659A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un uso de un inhibidor de PARP en el tratamiento de un cáncer de ovario o cáncer de mama resistente a la quimioterapia. En particular, la presente invención proporciona un uso de un inhibidor de PARP en la preparación de un fármaco para tratar un cáncer de ovario o cáncer de mama resistente a la quimioterapia. El inhibidor de PARP se selecciona de un compuesto como se muestra en la fórmula general (B) y una sal farmacéuticamente aceptable del mismo.
MX2020005659A 2017-12-06 2018-12-05 Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia. MX2020005659A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711278350 2017-12-06
PCT/CN2018/119318 WO2019109938A1 (zh) 2017-12-06 2018-12-05 Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途

Publications (1)

Publication Number Publication Date
MX2020005659A true MX2020005659A (es) 2020-08-20

Family

ID=66751288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005659A MX2020005659A (es) 2017-12-06 2018-12-05 Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.

Country Status (11)

Country Link
US (1) US20200281923A1 (es)
EP (1) EP3721906A4 (es)
JP (1) JP2021505548A (es)
KR (1) KR20200096788A (es)
CN (2) CN113768933B (es)
AU (1) AU2018380174A1 (es)
BR (1) BR112020010435A2 (es)
CA (1) CA3080644A1 (es)
MX (1) MX2020005659A (es)
TW (1) TW201924720A (es)
WO (1) WO2019109938A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
TW202110448A (zh) * 2019-05-28 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途
CN114058700A (zh) * 2020-07-29 2022-02-18 深圳微芯生物科技股份有限公司 Rbm10基因的用途
CN115105599A (zh) * 2021-03-17 2022-09-27 四川大学 一种抗肿瘤的联合用药物及其应用
AU2022276986B2 (en) * 2021-05-18 2025-07-03 Onconic Therapeutics Inc. Parp inhibitor-resistant cancer therapeutic agent
KR20240153590A (ko) * 2022-02-24 2024-10-23 아케소 파마슈티컬스, 인코포레이티드 항-ctla4-항-pd-1 이중특이적 항체 및 치아우라닙을 포함하는 약제학적 조성물
WO2024099387A1 (zh) * 2022-11-09 2024-05-16 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗癌症
WO2025225834A1 (ko) * 2024-04-25 2025-10-30 한국 한의학 연구원 루카파립 캄실레이트를 유효성분으로 함유하는 항암제 내성암의 예방 또는 치료용 약학 조성물
CN120324628B (zh) * 2025-04-16 2026-01-30 上海生物制品研究所有限责任公司 叶酸偶联物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129252B2 (en) 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
CN101676267B (zh) 2008-09-16 2012-12-26 江苏恒瑞医药股份有限公司 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
AR075239A1 (es) * 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
US20120039805A1 (en) 2009-02-20 2012-02-16 Pangea Biosciences, Inc. Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2016116602A1 (en) 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
TWI771344B (zh) * 2016-12-01 2022-07-21 大陸商江蘇恆瑞醫藥股份有限公司 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途
US11801240B2 (en) * 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
BR112020015909A2 (pt) * 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico

Also Published As

Publication number Publication date
JP2021505548A (ja) 2021-02-18
AU2018380174A1 (en) 2020-05-21
CN113768933A (zh) 2021-12-10
CA3080644A1 (en) 2019-06-13
EP3721906A4 (en) 2021-08-04
WO2019109938A1 (zh) 2019-06-13
CN111093706B (zh) 2022-06-21
CN113768933B (zh) 2024-02-20
US20200281923A1 (en) 2020-09-10
RU2020119898A (ru) 2022-01-10
KR20200096788A (ko) 2020-08-13
EP3721906A1 (en) 2020-10-14
BR112020010435A2 (pt) 2020-11-24
CN111093706A (zh) 2020-05-01
TW201924720A (zh) 2019-07-01
RU2020119898A3 (es) 2022-01-19

Similar Documents

Publication Publication Date Title
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
EP4302835A3 (en) Methods of treating ovarian cancer
JOP20190254A1 (ar) مركبات مضادة للأورام
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
EA201790376A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX381994B (es) Inhibidor de janus quinasa.
GEP20186933B (en) Substituted dihydroisoquinoline compounds
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
ZA201902335B (en) Pharmaceutical compounds
GEAP202014982A (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CO2017000362A2 (es) Compuestos de derivados heterocíclicos sustituidos como inhibidores de demtilasa-1 específica lisina
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
MX376207B (es) Inhibidores de demetilasa-1 especifica de lisina.
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX393711B (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres
PH12016502246B1 (en) Carboxamide derivatives
EA201492104A1 (ru) Ингибитор jak1/2
MY193239A (en) Novel b-lactamase inhibitors
MX2019002065A (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana.
EA201692332A1 (ru) Борсодержащие ингибиторы протеасом для применения после первичной противораковой терапии
IN2014MU00495A (es)
PH12018501100A1 (en) Phenylimidazole compound